TABLE OF CONTENTS 

Preamble 

I. Introductiou 

IL. Summary of Terms of the Order 

III. Contents ofPMN 

N. EPA's Assessment of Risk 

V. EPA's Conclusions of Law 

VI. Information Required to Evaluate Human Health Effects 

Consent Order 

I. . Scope of Applicability and Exemptions 

II. Terms of Manufacture, Import, Processing, Distribution in Commerce, Use, and Disposal 

Pending Submission and Evaluation ofInformation 

III. R(:(;Qr<ik:ee'pin~ 

IV. Requests for Pre-Inspection Information 

V. Successor Liability Upon Transfer of Consent Order 

VI. Modification and Revocation of Consent Order 

VII. Effect of Consent Order 

Attaclunent A - Definitions 

Attaclunent B - Notice of Transfer of Consent Order 
iii 

PREAMBLE 

I INTRODUCTION 

Under the authority of § 5(e) of the Toxic Substance Control Act ("TSCA") (15 U.S.C. 

2604( e)), the Environmental Protection Agency ("EPA" or "the Agency") issues the attached 

Order, regarding premanufactnre notice ("PMN") P-09-417 for the chemical substance, short 

tangled multi-wall carbon nanotubes (MWCNT) obtained by catalytical vapor deposition, (the 

"PMN substance"), submitted by Nanocyl Corporation, a Georgia Corporation ("the 

Company"), to take effect upon expiration of the PMN review period. The Company submitted 

the PMN to EPA pursuant to section 5(a)(I) of TSCA and 40 CFRPart 720. 

Under § 15 of TSCA, it is unlawful for any person to fail or refuse to comply with any 

provision of § 5 or any order issued under § 5. Violators may be subject to various penalties and 

to both criminal and civil liability pursuant to § 16, and to specific enforcement and seizure 

pursuant to § 17. In addition, chemical substances subject to an Order issued under § 5 of 

TSCA, such as this one, are subject to the § 12(b) export notice requirement. 

II. SUMMARY OF TERMS OF THE ORDER 

The Consent Order for this PMN substance requires the Company to: 

(1) Submit certain physical-chemical data within 13 months after the date of commencement 

of nonexempt commercial manufactnre or import of the PMN substance; 

2) Submit a 1 gram sample of the PMN substance with MSDS to EPA upon request; 

3) Provide workers with impervious gloves and chemical protective clothing in the work area 

whenever likely to be exposed to the PMN substance dermally in the work area; 
IV 

4) Provide workers with a full-face NIOSH-approved respirator with an N -100 cartridge 

to prevent inhalation exposure in the work area; 

5) Import, process, and use the PMN substance only as: Plastics additive to improve electrical, 

thermal, and/or mechanical properties. 

6) Not mannfacture the substance in the United States (import only); 

7) Comply with the Release to Water provisions; 

8) Distnbute the PMN substance only to a person who agrees to follow the same 

restrictions (except the testing requirements and not to further distribute the substance unless it 

has been completely reacted (cured); embedded or incorporated into a polymer matrix that has 

been reacted (cured); or embedded in a permanent solid polymer form that is not intended to 

undergo further processing, except mechanical); and 

9) Maintain certain records. 

III. CONTENTS OF PMN 

By signing this Order, the Company represents that it has carefully reviewed this 

document and hereby agrees that all information herein that is claimed as confidential by the 

Company (per section 14 ofTSCA, 40 CFR Part 720 Subpart E, and 40 CFR Part 2) is correctly 

identified within brackets and that any information that is not bracketed is not claimed as 

confidential. To make this document available for public viewing, EPA will remove only the 

information contained within the brackets. 

Confidential Business Information Claims (Bracketed in the Preamble and Order): 

Precursor substances, impurities, production volUllle, risk management, particle size distribution, 

process information, impurities, byproducts. 
v 

Chemical Identity: multi-wall carbon nanotubes. 

Use: Plastics additive to improve electrical, thelIDal, and/or mechanical properties. 

Maximum 12-Month Production Volume: [ 1 kg/yr. 

Test Data Submitted with PMN: Particle size infolIDation, subchronic inhalation study, 

subacute inhalation study, basal cytotoxicity, genotoxicity, and physico-chemical 

properties. 

IV. EPA'S ASSESSMENT OF RISK 

The following are EPA's predictions regarding the probable toxicity, human exposure 

and environmental release of the PMN substance, based on the information currently available to 

the Agency. 

Human Health Effects Summary: 

Absorption is expected to be poor via all routes based on test data for chemicals with 

similar molecular structures and chemicals with similar physical/chemical properties. There are 

concerns for lung effects based on the EPA Respirable, Poorly Soluble Particulates chemical 

category. See www.epa.gOv/opptlnewchems/pubs/cat02.htm#Respirable. 

There are concerns for lung overload for poorly soluble particulates and for lung effects based on 

test data submitted with P09-417. There are possible concerns for immunotoxicity, oncogenicity 

and mutagenicity based on analogs. The major health concerns for the PMN substance are for 

potential pulmonary toxicity, fibrosis and cancer to workers exposed via the inhalation route. 

There are also data suggesting that pulmonary deposition of some nanoparticles, including 

carbon nanotubes, may induce cardiovascular toxicity when inhaled. 
VI 

Environmental Effects Summary: 

Toxicity from carbon nanotnbes, "CNT", exposures has been reported in many species at 

concentrations much higher than any estimated solubility limits. Even though CNTs are not 

appreciably water soluble as manufactured, aqueous CNT suspensions can be easily made 

through reaction with strong acids, ozone, or dispersing agents. Recent laboratory research 

shows that CNTs combine with dissolved organic matter (DOM) to form stable aqueous 

suspensions. No stndies on CNTs are available in which a broad range of production methods, 

sources, purification, functionalization, etc. were investigated. EPA expects that some fraction 

of the CNTs, if released into the environment, will eventnally become suspended in water. 

Sublethal effects have been noted for single-walled carbon nanotnbes ("SWCNT") in rainbow 

trout at levels as low as 100 ppb. Noted effects included respiratory stress, ventilation rate, gill 

mucus secretion, gill damage, and aggressive behaviors. Liver cell injuries were also readily 

apparent at these exposure levels and suggest the possibility ofliver tnmor formation over longer 

exposure periods. This response is also notable because effects were seen in cells closest to blood 

vessels, suggesting transport of respired or ingested SWCNTs via the blood stream. Some effects 

in the gut lumen were also observed at these exposure levels. Further stndies need to be 

conducted before EPA can determine a concentration of concern. Such stndies must measure 

actnal concentrations of carbon nanotubes and control for the effects of contaminants, solvents, 

and physical factors such as blockage of gills or intestines. Before such testing is conducted, 

advanced fate testing would be necessary to ascertain what substance is likely to present the 

bighest environmentally relevant concentrations. 
vii 

Exposure and Environmental Release Summary: 

Scenario Processing 1 Processing 2 Use 

# Sites [ ] [] [] 

Workers [] [] [] 

(#/site) 

Exposure 250 250 250 

(days/year) 

Dermal ExposUre 6 6-8 8 

(mg/day) 

Inhalation Exposure 0.0018 0.2 negligible 

(mg/day) 

Drinking Water NA NA· NA 

Exposure (mg/day) 

Releases (kg/year) [] [] [] 

Release to water none none none 

(kg/day) 

. 

Risk to Workers: The PMN substance may present a risk to workers exposed to the PMN 

substance via inhalation. 

V. EPA'S CONCLUSIONS OF LAW 

The following findings constitute the basis of the Consent Order: 

(a) EPA is unable to determine the potential for human health and environmental effects from 

exposure to the PMN substance. EPA therefore concludes, pursuant to § 5( e )(1 )(A)(i) of TSCA, 

that the information available to the Agency is insufficient to permit a reasoned evaluation of the 

human health effects of the PMN substance. 
viii 

(b) In light of the potential risk to hnman health and the environment posed by the uncontrolled 

manufacture, import, processing, distribution in commerce, use, and disposal of the PMN 

substance, EPA has concluded, pursuant to § 5( e)(1 )(A)(ii)(I) of TSCA, that uncontrolled 

manufacture, import, processing, distribution in commerce, use, and disposal of the PMN 

substance may present an unreasonable risk of injury to human health. 

VI. INFORMATION REQUIRED TQ EVALUATE HEALTH EFFECTS 

Triggered Testing. The Order prohibits the Company from exceeding a specified 

production limit unless the Company submits the information described in the Testing 

section of this Order in accordance with the conditions specified in the Testing section. 

Pended Testing. The following additional information would be required to evaluate 

human health and enviromnental effects which may be caused by the PMN substance: 

Information 

Combined Toxicity/Carcinogenicity 

Testing of Respirable Fibrous Particles 

Guidelines 

OPPTS 870.8355 

The Order does not require submission of the above pended testing at any specified time or 

production volume. However, the Order's restrictions on manufacture, import, processing, 

distribution in commerce, use, and disposal of the PMN substances will remain in effect until the 

Order is modified or revoked by EPA based on submission of that or other relevant information. 
UNITED STATES ENVIRONMENTAL PROTECTION AGENCY 

WASHINGTON, D.C. 20460 

CONSENT ORDER 

I. SCOPE ()FAPPLICABILITY AND EXEMPTIONS 

-OFFICE OF 

PREVENTION, PESTlCII)ES AND 

TOXIC SUBSTANCES 

, . . -

(a) Scope. The requirements of this Order apply to all commercial manufacturing, processing, 

distribution in commerce, use and disposal, in the United States, oIthe short tangled multi-wall 

carbon nanotubes ("MWCN") obtained by catalytical vapor deposition,( the "PMN substance"), 

submitted by Nanocyl Corporation, a Georgia Corporation ("the Company"), except to the extent 

that those activities are exemptedby paragraph (b). 

(b) Exemptions. Manufacturing, processing, distribution in commerce, use and disposal of the 

PMN substance are exempt from the. requirements of this Order (except the requirements in the 

'R~¢grcl[~_~Iiiiig:!ill(LSiip~~~®r LIatility1JJiQn ILaii~[er9f <;oi1~ejJfOi~r§~(;ti6iis) Ql1!yfo!lie 

extent that (I) these activities are conducted in full compliance with all applicable requirements 

of the following exemptions, and (2) such compliance is documented by appropriate 

recordkeeping as required in the Recordkeeping section of this Order. 

(I) Completely Reacted (Cured). If quantities of the PMN s.ubstance (A) are used solely 

for the purpose authorized in paragraph b(i) under the Manufacturing section and paragraph (a) 

of the ProcessinglUse section of this Order; and (B) those quantities have been (i) completely 

reacted (cured); (ii) embedded or incorporated into a polymer matrix that itself has been reacted 

Internet Address (URL). http://www.epa.gov . 

Recycled/Recyclable. Printed with Vegetable Oil Based Inks on 10.0.% Postconsumer, Process Chlorine Free Recycled Paper 

(j 

o 

z 

o);! 

OJ- -2: 

en 

Z 

o 
2 

(cured); (iii) or embedded in a penuanent solid polymer fonn that is not intended to undergo 

further processing, except mechanical processing; then the requirements of this Order do not 

apply. 

(2) Export. Until the Company begins commercial manufacture of the PMN substance 

for use in the United States, the requirements of this Order do not apply to manufacture, 

processing or distribution in commerce of the PMN substance solely for export in accordance 

with TSCA §12(a) and (b), 40 CFR 720.3(s) and 40 CFR Part 707. However, once the Company 

begins to manufacture the PMN substance for use in the United States, no further activities by 

the Company involving the PMN substance are exempt as "solely for export" even if some 

amounts of the PMN substance are later exported. At that point, the requirements of this Order 

apply to all activities associated with the PMN substance while in the territory of the United 

States. Prior to leaving U.S. territory, even those quantities or batches of the PMN substance that 

are destined for export are subject to tenus of the Order, and count towards any production 

volume test triggers in the Testing section of this Order. 

(3) Research & Development ("R&D"). The requirements of this Order do not apply to 

manufacturing, processing, distribution in commerce, use and disposal of the PMN substance in 

small quantities solely for research and development in accordance with TSCA §5(h)(3), 40 CFR 

720.3(cc), and 40 CFR 720.36. 

(4) Byproducts. The reqnirements of this Order do not apply to the PMN substance 

when it is produced, without separate commercial intent, only as "byproducts" as defined at 40 

CFR nO.3( d) and in compliance with 40 CFR nO.30(g). 

(5) No Separate Commercial Pmpose. The requirements of this Order do not apply to 
2 

the PMN sUbstance when it is manufactured, pursuant to any of the exemptions in 40 CFR 

720.30(h), with no commerCial purpose separate from the substance, mixture, or article of which 

it is a part 

( c) Automatic Sunset. If the Company has obtained for the PMN substance a Test Market 

Exemption ("TME") under TSCA §5(h)(1) and 40 CFR 720.38 or a Low Volume Exemption 

. ("LVE") or Low Release and Exposure Exemption ("LoREx") under TSCA §5(h)(4) and 40 

CFR 723.50( c) (1 ) and (2) respectively, any such exemption is automatically rendered null and 

void as of the effective date of this Consent Order. 

II. TERMS OF MANUFACTURE, IMPORT, PROCESSING, 

DISTRIBUTION IN COMMERCE, USE, AND DISPOSAL 

PENDING SUBMISSION AND EVALUATION OF INFORMATION 

PROHIBITION 

The Company is prohibited from manufacturing, importing, processing, distributing in 

commerce, using, or disposing of the PMN substance in the United States, for any nonexempt ---- ----------- - ------ - --- -- ~ --~~ -- -- - ---- ---- - -- -- - -

commercial purpose, pending the development of information necessary for a reasoned 

evaluation of the human health effects of the substance, and the completion ofEP A's review of, 

and regulatory action based on, that information, except in accordance with the conditions 

described in this Order. 

TESTING 

(a) Section 8ee) Reporting. Reports of information on the PMN substance which reasonably 
4 

supports the conclusion that the PMN substance present a substantial risk of injury to health or 

the environment and which is required to be reported under EPA's section 8( e) shall reference 

the appropriate PMN identification number for this substance and contain a statement that the 

substance is subject to this Consent Order. Additional information regarding section (8) 

reporting requirements can be found atwww.t<Qa.gov/optitsca8e 

(b) Notice of Study Scheduling. The Company shall notifY, in writing, the EPA Laboratory 

Data lntegrity Branch (2225A), Office of Enforcement and Compliance Assurance, U.S. 

Environmental Protection Agency, 1200 Pennsylvania Avenue, N.W., Washington, D.C. 20460, 

of the following information within 10 days of scheduling any study required to be performed 

pursuant to this Order, or within 15 days after the effective date of this Order, whichever is later~ 

(1) The date when the studyis scheduled to commence; 

(2) The name and address of the laboratory which will conduct the study; 

(3) The name and telephone number of a person at the Company or the laboratory whom 

EPA may contact regarding the study; and 

(4) The appropriate PMN identification number for the substance mid a statement that 

the substance is subject to this Consent Order. 

(c) Good Laboratory Practice Standards and Test Protocols. Each study required to be 

performed pursuant to this Order must be conducted according to TSCA Good Laboratory 

Practice Standards at 40 CFR Part 792 and using methodologies generally accepted in the 

relevant scientific commuuity at the time the study is initiated. Before starting to conduct any 

such study, the Company must obtain approval of test protocols from EPA by submitting written 
5 

protocols. EPA will respond to the Company within 4 weeks of receiving the written protocols. 

Published test guidelines specified in paragraph (d) provide general guidance for development of 

test protocols, but are not themselves acceptable protocols. Approval of the test protocol does 

not mean pre-acceptance oftest results. 

(d) Triggered Testing Requirements. The Company is prohibited from manufacturing or 

,importing, or causing another person to manufacture or import of the PMN substance beyond 13 

months after the date of commencement of nonexempt commercial manufacture or import of the , 

PMN substance ("the production limit"), unless the Company provides the following data for the 

PMN substance and submits all final reports and underlying data in accordance with the, 

conditions specified in this Testing section: 

1. Dry particle size distribution as used in the workplace at sites controlled by the Company 

where the PMN substance is manufactured or processed: STEM (scanning transmission 

electron microscopy) using a dry particle counting method, no counting after dispersion in a 

solution and evaporating solvent, with a resolution of < 1 nanometer. Dry particle size 

distribution information should include the fraction of the particle distribution that is in the 

respirable range of up to 10 microns. 

2. Dustiness (EN 15051 method). 

3. Using the STEM, TEM, or SEM method (whichever the Company deems is best) 

determine the following; 

-- Number of walls: range and average 

Tube ends: open, capped, circular, other 

Tube width/diameter: measure inner and outer diameters (give range) 

Describe any deformities found in the tubes: bumps, branching, gaps, etc. 

Description of the physical-chemical properties ofthe material tested should take into 

consideration the characterizations identified in the Guidance Manual for Sponsors of the OECD 

Sponsorship Programme for the Testing of Manufactured Nanomaterials. 
6 

(e) Test Reports. The Company shall: (1) conduct each study in good faith, with due care, and 

in a scientifically valid manner; (2) promptly furnish to EPA the results of any interim phase of 

each study; and (3) submit, in triplicate (with an additional sanitized copy, if confidential 

business information is involved), the final report of each study and all underlying data ("the 

report and data") to EPA no later than 14 weeks prior to exceeding the applicable production 

limit. The final report shall contain the contents specified in 40 CFR 792.185. Underlying data 

shall be submitted to EPA in accordance with the applicable "Reporting", "Data and Reporting", 

and "Test Report" subparagraphs in the applicable test guidelines. However, for purposes of this 

Consent Order;the word "should" in those subparagraphs shall be interpreted to mean "shall" to 

make clear that the submission of such information is mandatory. EPA will not require the 

submission of raw data such as slides and laboratory notebooks unless if EPA finds, on the basis 

of professional judgment, that an adequate evaluation of the study cannot take place in the 

absence of these items. 

(f) Testing Waivers. The Company is not required to conduct a study specified in paragraph (d) 

of this Testing section if notified in writing by EPA that it is unneoessary to conduct that study. 

(g) Equivocal Data. If EPA finds that the data generated by a study are scientifically equivocal, 

the Company may continue to manufacture and import the PMN substance beyond the applicable 

production limit. To seek relief from any other restrictions of this Order, the Company may 

make a second attempt to obtain unequivocal data by reconducting the study under the conditions 

specified in paragraphs (b), (c), and (e)(1) and (2). The testing requirements may be modified, as 

necessary to permit a reasoned evaluation of the risks preseuted by the PMN substance, ouly by 
7 

mutual consent of EPA and the Company . 

. (h) EPA Determination ofInvalid Data. 

(1) Except as described in subparagraph (h)(2), it; within 6 weeks ofEP A's receipt of a 

test report and data, the Company receives written notice that EPA finds that the data generated 

by a study are scientifically invalid, the Company is prohibited from further manufacture and 

import of the PMN substance beyond the applicable production limit. 

(2) The Company may continue to manufacture and import the PMN substance beyond 

the applicable production limit only if so notified, in writing, by EPA in response to the 

Company's compliance with either of the following subparagraphs (h)(2)(i) or (h)(2)(ii). 

(i) The Company may reconduct the study in compliance with paragraphs (b), 

(c), and (e)(l) and (2). If there is sufficient time to reconduct the study and submit the report and 

data to EPA at least 14 weeks before exceeding the production limit as required by subparagraph 

(e )(3), the Company shall comply with subparagraph (e )(3). If there is insufficient time for the 

Company to comply witlJ. subparagraph (f)(3), the Company may exceed the production limit and 

shall submit the report and data in triplicate to EPA within a reasomibfe penod oIume, ail as 

specified by EPA in the notice described in subparagraph (h)(I). EPA will respond to the 

Company, in writing, within 6 weeks of receiving the Company's report and data. 

(ii) The Company may, within 4 weeks of receiving from EPA the notice 

described in subparagraph (h)(I), submit to EPA a written report refuting EPA's finding. EPA 

will respond to the Company, in writing, within 4 weeks of receiving the Company's report. 
8 

(i) Company Determination of Invalid Data. 

(1 )Except as described in subparagraph (i)(2), if the Company becomes aware that 

circumstances clearly beyond the control of the Company or laboratory will prevent, or have 

prevented, development of scientifically valid data under the conditions specified in paragraphs 

( c) and ( e), the Company remains prohibited from further manufacture and import of the PMN 

substance beyond the applicable production limit. 

(2) The Company may submit to EPA, within 2 weeks of first becoming aware of such 

circumstances, a written statement explaining why circumstances clearly beyond the control of 

. the Company or laboratory will cause or have caused development of scientifically invalid data 

EPA will notifY the Company of its response, in writing, within 4 weeks of receiving the 

Company's report. EPA's written response may either: 

(i) allow the Company to continue to manufacture and import the PMN substance 

beyond the applicable production limit, or 

(ii) require the Company to continue to conduct, or to reconduct, the study in 

compliance with paragraphs (b), (c), and (e)(1) and (2). Ifthere is sufficient time to conduct or 

recondnct the study and submit the report and data to EPA at least 14 weeks before exceeding 

the production limit as required by subparagraph (e )(3), the Company shall comply with 

. subparagraph (e )(3). If there is insufficient time for the Company to comply with subparagraph 

(e)(3), the Company may exceed the production limit and shall submit the report and data in 

triplicate to EPA within a reasonable period of time, all as specified by EPA in the notice 

described in subparagraph (i)(2).' EPA will respond to the Company, in writing, within 6 weeks 

of receiving the Company's report and data, as to whether the Company may continue to 

manufacture and import beyond the applicable production limit. 
9 

0) Unreasonable Risk. 

(1) EPA may notify the Company in writing that EPA finds that the data generated by a 

stndy are scientifically vaiid and unequivocal and indicate that, despite the terms of this Order, 

the PMN substance will or may present an unreasonable risk of injury to human health or the 

envirornnent. EPA's notice may specify that the Company undertake certain actions concerning 

further testing, manufacture, import, processing, distribution, use and! or disposal of the PMN 

substance to mitigate exposures to or to better characterize the risks presented by the PMN 

substance. Within 2 weeks from receipt of such a notice, the Company must cease all 

manufacture, import, processing, distribution, use and disposal of the PMN substance, unless 

either: 

(2) within 2 weeks from receipt ofthe notice described in subparagraph G)(l), the 

Company complies with such requirements as EPA's notice specifies; or 

(3) within 4 weeks from receipt of the notice described in subparagraph 0)(1), the 

Company submits to EPA a written report refuting EPA's finding and!or the appropriateness of 

any additional requirements imposed by EPA. The Company may continue to manufactnre, 

import, process, distribute, use and dispose of the PMN substance in accordance with the terms 

of this Order pending EPA's response to the Company's written report. EPA will respond to the 

Company, in writing, within 4 weeks of receiving the Company's report. Within 2 weeks of 

receipt ofEP A's written response, the Company shall comply with any requirements imposed by 

EPA's response or cease all manufacture, import, processing, distribution, use and disposal of 

the PMN substance. 
10 

(k) Other Requirements. Regardless of the satisfaction of any other conditions in this Testing 

section, the Company must continue to obey all the terms of this Consent Order until otherwise 

notified in writing by EPA. The Company may, based upon submitted test data or other relevant 

information, petition EPA to modif'y or revoke provisions of this Consent Order pursuant to Part 

VI of this Consent Order. 

PROTECTION IN THE WORKPLACE 

(a) Establishment of Pro gram. During manufacturing, processing, and use of the PMN substance 

at any site controlled by the Company (including any associated packaging and storage and 

during any cleaning or maintenance of equipment associated with the PMN substance), the 

Company must establish a program whereby: 

(1) General D=al Protection. Each person who is reasonably likely to be dermally 

exposed in the work area to the PMN substance through direct handling of the substance or 

through contact with equipment on which the substance may exist, or because the substance 

become airborne in a form listed in subparagraph (a)(5) of this section, is provided with, and is 

required to wear, personal protective equipment that provides a barrier to prevent dermal 

exposure to the substance in the specific work area where the substance are selected for use. 

Each such item of personal protective eq~ipment must be selected and used in accordance with 

OSHA d=al protection requirements at 29 CPR 1910.132, 1910.133, and 1910.138. 

(2) Specific Dermal Protective Equipment. The d=al personal protective equipment 

required by subparagraph (a)(I) of this section must include, but is not limited to, the following 

items: 
11 

(i) Gloves impervious to the PMN substance 

(ii) Full body clothlng impervious to the PMN substance 

(3) Demonstration of Imperviousness. The Company is able to demonstrate that each 

item of chem.ical protective clothing selected, including gloves, provides an impervious barrier to 

prevent dermal exposure during normal and expected duration and conditions of exposure within 

the work area by anyone or a combination of the following: 

(i) Permeation Testing. Testing the material used to make the chemical protective 

clothlng and the construction of the clothing to establish that the protective clothiug will be 

impervious for the expected duration and conditions of exposure. The testing must subject the 

chemical protective clothing to the expected conditions of exposure, inCluding the likely 

combinations of chemical substance to which the clothing may be exposed in the work area. 

Permeation testing may be conducted according to the American Society for Testing and 

Materials ("ASTM") F739 "Standard Test Method for Resistance of Protective Clothing 

materials to Permeation by Liquids or Gases." Results shall be recorded as a cumulative 

permeation rate as a function of time, and shall be documented in accordance with ASTM F739 

using the format specified in ASTM Fl194-89 "Guide for Documenting the Results of Chemical 

Permeation Testing on Protective Clothing Materials." Permeation testing may also be 

conducted according to the ASTM F1671-07 "Standard Test Method for Resistance of Materials 

Used in Protective Clothing to Penetration by Blood-Borne Pathogens Using Phi-X174 

Bacteriophage Penetration as a: Test System". Gloves may not be used for a time period longer 

than they are actually tested and must be replaced at the end of each work shift during which 

they are exposed to the PMN substance. 

(ii) Manufacturer's Specifications. Evaluating the specifications from the 
12 

manufacturer or supplier of the chemical protective clothing, or of the material used in 

construction of the clothing, to establish that the chemical protective clothing will be impervious 

to the PMN substance alone and in likely combination with other chemical substance in the work 

area. 

(4) Respiratory Protection. Each person who is reasonably likely tobe exposed by 

inhalation in the work area to the PMN substance in the form listed in subparagraph (a)(5) of this 

section, is provided with, and is required to wear, at a minimum, a National Institute for 

Occupational Safety and Health ("NIOSH")-certified respirator with an Applied Protection 

Factor (APF) of 50 from the respirators listed in subparagraph (a)(6) of this section, and the 

respirator is used in accordance with the Occupational Safety and Health Administration 

("OSHA") and NIOSH respiratory protection requirements at 29 CFR 1910.134 and 42 CFR Part 

84. All respirators must be issued, used, and maintained according to an appropriate respiratory 

protection program under the OSHA requirements in29 CFR 1910.134. 

(5) Physical States. The following physical states of airborne chemical substance are 

. listed for subparagraphs (a)(I) and (4) of this section: 

(i) Particulate (including solids or liquid droplets). 

(6) Authorized Respirators. The followingNIOSH-certified respirators 

meet the minimum requirements for subparagraph (a)(4) of this section: NIOSH-certified airpurifYing, tight-fitting full-face respirator equipped with N100, P-I00, or R-I00 filter. 

MANUFACTURING 

(a)(1) Prohibition. The Company shall not cause, encourage, or suggest the manufacture or 

import of the PMN substance by any other person. 
13 

(2) Sunset Following SNUR. Subparagraph (a)(1) shall expire 75 days after promulgation of 

a final significant new use nile ("SNUR") governing the PMN substance under section 5(a)(2) of 

TSCA unless the Company is notified on or before that day of an action in a Federal Court 

seeking judicial review of the SNUR. lfthe Company is so notified, subparagraph (a)(l) shall 

not expire until EPA notifies the Company in writing that all Federal Court actions involving the 

SNUR have beel1 resolved and the validity of the SNUR affirmed. 

(3) Notice of SNUR. When EPA promulgates a final SNUR for the PMN substance and 

subparagraph (a)(l) expires in accordance with subparagraph (a)(2), the Company shall notifY 

each person whom it causes, encourages or suggests to manufacture or import the PMN 

substance of the existence of the SNUR. 

(b) Prohibited Uses. The Company shall not import the PMN substance for use other than as 

plastics additive to improve electrical, thermal, and/or mechanical properties. 

(c) The Company shall provide to EPA a 1 gram sample of the PMN substance as specified 

by EPA in a future written request along with a copy of the MSDS for the substance. 

PROCESSING AND USE 

(al The Company shall not process or use the PMN substance other than as a plastics 

additive to improve electrical, thermal, and/or mechanical properties. 

(b) The Company shall not process or use the non-exempt PMN substance for commercial or 

consumer use. 
14 

DISTRIBUTION 

(a) Export Notice Requirement No later than the date of distribution, the Company shall notify 

in writing any person to whom it distributes the PMN substance that, due to the issuance of this 

Consent Order under section 5( e) ofTSCA, the PMN substance is subject to the export 

notification requirements ofTSCA section 12(b) and 40 CFR Part 707 Subpart D. Such notice 

shall contain, in the form in which they appear in the Consent Order, the following information: 

(1) the PMN number and (2) either (A) the specific chemical identity of the chemical substance, 

or (B) if the specific chemical identity is confidential, the generic chemical identity. 

(b) Distribution Requirements. (i) Except after the PMN substance has been completely reacted 

(cured); embedded or incorporated into a polymer matrix that has been reacted (cured); or 

embedded in a permanent solid polymer form that is not intended to undergo further processing, 

except for mechanical processing, or as provided in paragraph ( c) the Company shall distribute 

the PMN substance outside the Company, other than for disposal, only to a person who has 

agreed in writing prior to the date of distribution, to: 

(1) Notify in writing any person to whom it distributes the PMN substance that, due to 

the issuance of this Consent Order under section 5( e) of TSCA, the PMN substance is subject to 

the export notification requirements ofTSCA section 12(b) and 40 CFR Part 707 SubpartD. 

Such nqtice shall contain, in the form in which it appears in this Consent Order, the following 

information: (1) the PMN number, and (2) either (A) the specific chemical identity of the PMN 

substance, or (B) if the specific chemical identity is confidential, the generic chemical identity. 
15 

(2) Not further distribute the PMN substance to any other person, other than for disposal, 

until after the PMN substance has been completely reacted (cured); embedded or incorporated 

into a polymer matrix that has been reacted (cured); embedded in a permanent solid polymer 

form that is not intended to undergo further processing, except for mechanical processing. 

(3) Comply with the same requirements and restrictions required of the Company in the 

Protection in the Workplace section. 

(4) Not process or use the PMN substance other than as a plastics additive to improve 

electrical, thermal, and/or mechanical properties. 

(5) Not process or use the non-exempt PMN substance other than in industrial setup. 

(6) Comply with the same environmental release restrictions required of the Company in 

the Release to Water Section of the Order. 

(c) Temporarv Transport and Storage. Notwithstanding paragraph (b), the Company may 

distribute the PMN substance outside the Company for temporary transport and storage in sealed 

containers provided the following two conditions are met: 

(1) Subsequent to any such exempt temporary transport or storage of sealed containers, the 

PMN substance may be distributed only to the Company or a person who has given the Company 

the written agreement required by paragraph (b). 

(2) Any human exposure or environmental release resulting from opening the sealed 

containers and removing or washing out the PMN substance may occur only while the PMN 

substance are in the possession and control of the Company or a person who has given the 

Company the written agreement required by paragraph (b). 
16 

(d) Recipient Non-Compliance. If; at any time after commencing distribution in commerce of the 

PMN substance, the Company obtains knowledge that a recipient of the substance have failed to 

comply with any of the conditions specified in paragraph (b) of this Distribution section or, after 

subparagraph (b)(i)(2) expires in accordance with subparagraph (e)(l), has engaged in a significant 

new use of the PMN substanc;e (as defined in 40 CFR Part 721, Subpart E) without submitting a 

significant new use notice to EPA, the Company shall cease supplying the substance to that 

recipient, unless the Company is able to document each of the following: 

(1) That the Company has, within 5 working days, notified the recipient in writing that the 

recipient has failed to comply with any of the conditions specified in paragraph (b) of this 

Distribution section, or has engaged in a significant new use of the PMN substance without 

submitting a significant new use notice to EPA. 

(2) That, within 15 working days of notifying the recipient of the noncompliance, the 

Company received from the recipient, in writing, a statement of assurance that the recipient is 

aware of the terms of paragraph (b) of this Distribution section and will comply with those terms, 

or is aware of the terms of the significant new use rule for the PMN substai:tce and will not engage 

in a significant new use without submitting a significant new use notice to EPA 

(3) If, after receiving a statement of assurance from a recipient under subparagraph (d)(2) 

of this Distribution section, the Company obtains knowledge that the recipient has failed to comply 

with any of the conditions specified in paragraph (b) of this Distribution section, or has engaged in 

a significant new use of the PMN substance without submitting a significant new use notice to 

EPA, the Company shall cease supplying the PMN substance to that recipient, shall notify EPA of 

the failure to comply, and shall resume supplying the PMN substance to that recipient only upon 

written notification from the Agency. 
17 

(e) Sunset Following SNUR. (1) Subparagraph (b)(i)(2) of this Distribution section shall expire 

75 days after promulgation of a final SNUR for the PMN substance under section 5(a)(2) of 

TSCA, unless the Company is notified on or before that day of an action in a Federal Court 

seeking judicial review of the SNUR. If the Company is so notified, subparagraph (b )(i)(2) of this 

Distribution section shall not expire until EPA notifies the Company in writing that all Federal 

Court actions involving the SNUR have belm resolved and the validity of the SNUR affirmed. 

(2) When EPA promulgates a final SNUR for the PMN substance and subparagraph 

(b )(i)(2) of this Distribution section expires in accordance with subparagraph (e)(1), the Company 

shall notifY each person to whom it distributes the PMN substance of the existence of the SNUR. 

Such notification must be in writing and must specifically include all limitations contained in the 

SNUR which are defined as significant new uses, and which would invoke significant new use 

notification to EPA for the PMN substance. Such notice must also reference the publication of the 

SNUR for this PMN substance in either the Federal Register or the Code of Federal Regulations. 

After promulgation of a SNUR and expiration of subparagraph (b )(i)(2), such notice may 

substitute for the written agreement required in the introductory clause of paragraph (b); so that, if 

the Company provides such notice to the persons to whom it distributes the PMN substance, then 

the Company is not required to obtain from such persons the written agreement specified in 

paragraph (b). 

RELEASE TO WATER 

This provision does not supercede or preempt any applicable federal, state, or local laws and 

regulations. Those may be more stringent than the requirements below. 
18 

The Company is prohibited from any predictable or purposeful release of the PMN substance, or 

any waste stream from processing and use containing the PMN substance into the waters of the 

United States. 

RECORDKEEPING 

(a) Records. The Company shall maintain the following records until 5 years after the date they 

are created and shall make them available for inspection and copying by EPA in accordance with 

section 11 ofTSCA: 

(1) Exemptions. Records documenting that the PMN substance did in fact qualifY for any 

one or more of the exemptions described in Section I, Paragraph (b) of this Order. Such records 

must satisfY all the statutory and regulatory recordkeeping requirements applicable to the 

exemption being claimed by the Company. Anyamounts or batches of the PMN substance 

eligible for the Export exemption in Section I, Paragraph (b )(2) of this Order, are exempt from all 

the requirements in this Recordkeepingsection, if the Company maintains, for 5 years from the 

date of their creation, copies of the export label and export notice to EPA, required by TSCA 

sections l2(a)(1 )(B) and n(b), respectively. Any amounts or batches of the PMN substance 

eligible for the Research and Development exemption in Section 1, Paragraph (b )(3) of this Order, 

are exempt from all the requirements in this Recordkeeping section, if the Company maintains, for 

5 years from the date of their creation, the records required by 40 CFR nO.78(b). For any 

amounts or batches of the PMN substance claimed to be eligible for any other exemption described 

in Section I, Paragraph (b) of this Order, the Company shall keep records demonstrating 

qualification for that exemption as well as the records specified in paragraphs (2) and (3) below, 

but is exempt from the other recordkeeping requirements in this Recordkeeping section; 
19 

(2) Records documenting the manufacture and importation volume of the PMN substance 

and the corresponding dates of manufacture and import; 

(3) Records documenting the names and addresses (including shipment destination 

address, if different) of all persons outside the site of manufacture or import to whom the Company 

directly sells or transfers the PMN substance, the date of each sale or transfer, and the quantity of 

the substance sold or transferred· on such date; 

(4) Records documenting the addresses of all sites of manufacture, import, processing, and 

use; 

(5) Records documenting establishment and implementation of a program for the use of 

any applicable personal protective equipment required pursuant to the Protection in the Workplace 

section of this Order; 

(6) Records documenting the determinations required by the Protection in the Workplace 

section of this Order that chemical protective clothing is impervious to the PMN substance; 

(7) Records documenting compliance with any applicable manufacturing, processing, use, 

and distribution restrictions in the Manufacturing, Processing, and Use, and Distribution sections 

of this Order, including distributees' written agreement to comply with the Distribution section of 

this Order; 

(8) Records documenting establishment and implementation of procedures that ensure 

compliance with any applicable water discharge limitation in the Release to Water section ofthis 

Order; 

(9) Copies of any Transfer Documents and notices required by the Successor Liability 

section of this Order, if applicable; and 

(10) The Company shall keep a copy of this Order at each of its sites where the PMN 
20 

substance are manufactured of imported. 

(a) Applicability. The provisions of this Recordkeeping Section are applicable only to activities 

of the Company and its Contract Manufacturer, if applicable, and not to activities of the 

Company's customers. 

(b) OMB Control Number. Under the Paperwork Reduction Act and its regnlations at 5 CFR Part 

1320, particularly 5 CFR 1320.5(b), the Company is not required to respond to this "collection of 

information" unless this Order displays a currently valid control number from the Office of 

Management and Budget ("OMB"), and EPA so informs the Company. The "collection of 

information" required in this TSCA §5( e) Consent Orders has been approved under currently valid 

OMB Control Number 2070-0012. 

IV. REQUESTS FOR PRE-INSPECTION INFORMATION 

(a) EPA's Request for Information. Pursuantto section 11 of TSCA and 40 CFR 720.122, EPA 

may occasionally conduct on-site compliance inspections of Company facilities and conveyances 

associated with the PMN substance. To facilitate such inspections, EPA personnel may contact the 

Company in advance to request information pertinent to the scheduling and conduct of such 

inspections. Such requests may be written or oral. The types of information that EPA may request 

may include, but are not limited to, the following: 

(i) Expected dates and times when the PMN substance will be in production within the 

subsequent 12 months; 

(ii) Current workshift schedules for workers who are involved in activities associated with 
21 

the PMN substance and may reasonably be exposed to the PMN substance; 

(iii) Current job titles or categories for workers who are involved in activities associated 

with the PMN substance and may reasonably be exposed to the PMN substance; 

(iv) Existing exposure monitoring data for workers who are involved in activities 

associated with the PMN substance and may reasonably be exposed to the PMN substance; 

(v) Records required by the Recordkeeping section of this Order; and/or 

(vi) Any other information reasonably related to determining compliance with this Order or 

conducting an inspection for that ·purpose. 

(b) Company's Response. The Company shall respond to such requests within a reasonable period 

of time, but in no event later than 30 days after receiving EPA's request. When requested in 

writing by EPA, the Company's response shall be in writing. To the extent the information is 

known to or reasonably ascertainable to the Company at the time of the request, the Company's 

response shall demonstrate a good faith effort to provide reasonably accurate and detailed answers 

to all of EPA's requests. 

( c) Confidential Business Information. Any Confidential Business Information ("CBI") that the 

Company submits to EPA pursuant to paragraph (b) shall be protected in accordance with § 14 of 

TSCA and 40 CFR Part 2. 

V. SUCCESSOR LIABILITY UPON TRANSFER OF CONSENT ORDER 

(a) Scope. This section sets forth the procedures by which the Company's rights and obligations 

under this Order may be transferred when the Company transfers its interests in the PMN 
22 

substance, including the right to manufacture the PMN substance, to another person outside the 

Company (the "Successor in Interest"). 

(b) Relation of Transfer Date to Notice of Commencement ("NOC"). 

(1) Before NOC. If the transfer from the Company to the Successor in Interest is effective 

before EPA receives a notice of commencement of manufacture or import ("NOC") for the PMN 

substance from the Company pursuant to 40 CPR 120.102, the Successor in Interest must submit 

new PMNs to EPA and comply fully with Section S(a)(l) ofTSCA and 40 CPR part no before 

commencing manufacture or import of the PMN substance. 

(2) After NOC. If the transfer from the Company to the Successor in Interest is effective 

after EPA receives a NOC, the Successor in Interest shall comply with the terms of this Order and 

shall not be required to submit new PMNs to EPA 

(c) Definitions. The following definitions apply to this Successor Liability section ofthe Order: 

(1) "Successor in Interest" means a person outside the Company who has acquired the 

Company's full interest in the rights to manufacture the PMN substance, including all ownership 

rights and legal liabilities, through a transfer document signed by the Company, as transferor, and 

the Successor in Interest, as transferee. The term excludes persons who acquire less than the full 

interest of the Company in the PMN substance, such as a licensee who has acquired a limited 

license to the patent or manufacturing rights associated with the PMN substance. A· Successor in 

Lllterest must be incorporated, licensed, or doing business in the United States in accordance with 

40 CPR nO.22(a)(3). 

(2) "Transfer Document" means the legal instrument(s) used to convey the interests in the 
23 

PMN substance, including the right to manufacture the PMN substance, from the Company to the 

Successor in Interest. 

(d) Notices. 

(1) Notice to Successor in Interest. On or before the effective date of the transfer, the 

Company shall provide to the Successor in Interest, by registered mail, a copy of the Consent 

Order and the "Notice of Tninsfer" document which is incorporated by reference as Attachment C· 

to this Order. 

(2) Notice to EPA. Within 10 business days of the effective date of the transfer, the 

Company shall, byregistered mail, submit the fully executed Notice of Transfer document to: 

U.S. Environmental Protection Agency, New Chemicals Branch (7405), 1200 Pennsylvania 

Avenue, N.W., Washington, D.C. 20460. 

(3) Transfer Document. Copies of the Transfer Document must be maintained by the 

Successor in Iriterest at its principal place of business, and at all sites where the PMN substance are 

manufactured or imported. Copies of the Transfer Document must also be made available for 

inspection pursuant to Section 11 of TSCA, must state the effective date of transfer, and must 

contain provisions which expressly transfer liability for thePMN substance under the terms of this 

Order from the Company to the Successor in Interest. 

( e) Liability . 

. (1) The Company shall be liable for compliance with the requirements of this Order until 

the effective date of the transfer described above. 

(2) The Successor in Interest shall be liable for compliance with the requirements of this 
24 

Order effective as of the date of transfer. 

(3) Nothing in this section shall be constrned to prohibit the Agency from taking 

enforcement action against the Company after the effective date of the transfer for actions taken, or 

omissions made, during the time in which the Company manufactured, processed, used, distributed 

in commerce, or disposed of the PMN substance pursuant to the terms of this Consent Order. 

(f) Obligations to Submit Test Data under Consent Order. Ifparagraph (d) of the Testing section 

of this Consent Order requires the Company to submit test data to EPA at a specified production 

volume ("test trigger"), the aggregate volumeofthe PMN substance manufactured and imported 

by the Company up to the date of transfer shall count towards the test trigger applicable to the 

. Successor in Interest. 
25 

VI. MODIFICATION AND REVOCATION OF CONSENT ORDER 

The Company may petition EPA at any time, based upon new information on the health oe 

environmental effects of, or human or environmental exposure to, the PMN substance, to modify 

or revoke substantive provisions of this Order. The exposures and risks identified by EPA during 

its review of the PMN substance and the information EPA determined to be necessary to evaluate 

those exposures and risks are described in the preamble to this Order. However, in determining 

whether to amend or revoke this Order, EPA will consider all relevant information available at the 

time the Agency makes that determination, including, where appropriate, any reassessment of the 

test data or other information that supports the findings in this Order, an examination of new test 

data or other information or analysis, and anyother relevant information. 

EPA will issue a modification or revocation if EPA determines that the activities proposed 

therein will not present an unreasonable risk of injury to health or the environment and will not 

result in significant or substantial human exposure or substantial environmental release in the 

absence of data sufficient to permit a reasoned evaluation of the health or environtnental effects of 

the PMN substance. 

In addition, the Company may petition EPA at any time to make other modifications to the 

language of this Order. EPA will issue such a modification if EPA determines that the 

modification is useful, appropriate, and consistent with the structure and intent of this Order as 

issued. 
26 

VII. EFFECT OF CONSENT ORDER 

(a) Waiver. By consenting to the entry of this Order, the Company waives its rights to file 

objections to this Order pursuant to section 5(e)(1)(C) of TSCA, to receive service of this Order no 

later than 45 days before the end of the review period pursuantto section 5(e)(1)(B) ofTSCA, and 

to challenge the validity of this Order ill any subsequent action. Cons~nting to the entry of this 

Order, and agreeing to be bound by its terms, do not constitute an admission by the Company as to 

the facts or conclusions underlying the Agency's determinations in this proceeding. This waiver 

does not.affect any dth~r rights that the Company may have under TSCA. 

(b) CEl Brackets. By signmgthisOrder, the C~mpany represents that it has carefully reviewed· 

this document and hereby agrees thai all information herein that is claimed as confidential by the . . -.. . 

· Company(per section 14 ofTScA, 40 CFR Part 720 SubpartE, and 40 CFRPart 2) is correctly 

· identified within brackets and that any information that is not bracketed is not claimed as 

· confidential To make this docUment available for public viewing, EPA will remove only the 

information contained within the brackets. 

Date 

Da.J I 

'1 l 

ntro1 Division 

Office f oilution Prevention and Toxics 

N 

Title: Pr 

Company: Nanocyl Corporation, a Georgia 

Corporation 
ATTACHMENT A 

DEFINITIONS 

[Note: The attached Order may not contain some of the terms defined below.} 

"Chemical name" means the scientific designation of a chemical substance in accordance 

with the nomenclature system developed by the International Union of Pure and Applied 

Chemistry or the Chemical Abstracts Service's rules of nomenclature, or a name which will clearly 

identify a chemical substance for the purpose of conducting a hazard evaluation. 

"Chemical protective clothing" means items of clothing that provide a protective barrier to 

prevent dermal contact with chemical substance of concern. Examples can include, but are not 

limited to: full body protective clothing, boots, coveralls, gloves, jackets, and pants. 

"Company" means the person or persons subject to this Order. 

"Commercial use" means the use of a chemical substance or any mixture containing the 

chemical substance ill a commercial enterprise providing saleable goods or a service to consumers 

(e.g., a commercial dry cleaning establishment or painting contractor). 

"Common name" means any designation or identification such as code name, code number, 

trade name, brand name, or generic chemical name used to identify a chemical substance other 

than by its chemical name. 

"Consumer" means a private individual who uses a chemical substance or any product. 

containing the chemical substance in or around a permanent or temporary household or residence, 

during recreation, or for any personal use or enjoyment. 

"Consumer product" means a chemical substance that is directly, or as part of a mixture, 

sold or made available to consumers for their use in or around a permanent or temporary 

household or residence, in or around a school, or in recreation. 

"Container" means any bag, barrel, bottle, box, can, cylinder, drum, reaction vessel, storage 

tank, or the like that contains a hazardous chemical. For purposes of this section, pipes or piping 

systems, and engines, fuel tanks, or other operating systems in a vehicle, are not considered to be 

containers. 

"Contract Manufacturer" means a person, outside the Company, who is authorized to 

manufacture and import the PMN substance under the conditions specified in Part II. of this 

Consent Order and in the Consent Order for Contract Manufacturer. 

"Identity" means any chemical or common name used to identify a chemical substance or 

a mixture containing that substance. 

"Immediate use." A chemical substance is for the "immediate use" of a person if it is under 
2 

the control of, and used only by, the person who transferred it from a labeled container and will 

- only be used by that person within the work shift in which it is transferred from the labelled 

container. 

"Impervious." Chemical protective clothing is "impervious" to a chemical substance if the 

substance causes no chemical or mechanical degradation, p=eation, or penetration of the 

chemical protective clothing under the conditions of, and the duration of, exposure. 

"Manufacturing stream" means all reasonably anticipated transfer, flow, or disposal of a 

chemical substance, regardless of physical state or concentration, through all intended operations 

of manufacture, including the cleaning of equipment. 

"MSDS" means material safety data sheet, the written listing of data for the chemical 

substance. 

"NIOSH" means the National Institute for Occupational Safety and Health of the U.S. 

Department of Health and Human Services. 

"Non-enclosed process" means any equipment system (such as an open-top reactor, storage 

tank, or mixing vessel) in which a chemical substance is manufactured, processed, or otherwise 

used where significant direct contact of the bulk chemical substance and the workplace air may 

occur. 

"Non-industrial use" means use other than at a facility where chemical substance or 

mixtures are manufactured, imported, or processed. 

"PMN substance" means the chemical substance described in the Premanufacture notice 

submitted by the Company relevant to this Order. 

"Personal protective equipment" means any chemical protective clothing or device placed 

on the body to prevent contact with, and exposure to, an identified chemical substance or substance 

in the work area. Examples include, but are not limited to, chemical protective clothing, aprons, 

hoods, chemical goggles, face splash shields, or equivalent eye protection, and various types of 

respirators. Barrier creams are not included in this definition. . 

"Process stream" means all reasonably anticipated transfer, flow, or disposal of a chemical 

substance, regardless of physical state or concentration, through all intended operations of 

processing, including the cleaning of equipment. 

"Scientifically invalid" means any significant departure from the EPA-approved protocol 

or the Good Laboratory Practice Standards at 40 CFR Part 792 without prior or subsequent Agency 

approval that prevents a reasoned evaluation of the health or environmental effects of the PMN 

substance. 

"Scientifically equivocal data" means data which, although developed in apparent 
3 

conformity with the Good Laboratory Practice Standards and EPA-approved protocols, are 

inconclusive, internally inconsistent, or otherwise insufficient to permit a reasoned evaluation of 

the potential risk of injury to human health or the environment of the PMN substance. 

"Sealed container" means a closed container that is physically and chemically suitable for 

long-term containment of the PMN substance, and from which there will be no human exposure to, 

nor environmental release of, the PMN substance during transport and storage. 

"Use stream" means all reasonably anticipated transfer, flow, or disposal of a chemical 

substance, regardless of physical state or concentration, through all intended operations of 

industrial, commercial, or consumer use. 

"Waters of the United States" has the meaning set forth in 40 CFR 122.2. 

"Work area" means a room or defined space in a workplace where the PMN substance is 

manufactured, processed, or used and where employees are present. 

"Workplace" means an establishment at one geographic location containing one or more 

work areas. 
Company (Transferor) 

ATTACHMENTB 

NOTICE OF TRANSFER OF 

TOXIC SUBSTANCE CONTROL ACT 

SECTION See) CONSENT ORDER 

PMNNlimber 

1. Transfer of Manufacture Rights. Effective on , the Company did sell or 

otherwise transfer to , ("Successor in Interest") the rights 

and liabilities associated with manufacture of the above-referenced chemical substance, which was 

the subject ofa premanufacture notice ("PMN") and is governed by a Consent Order issued by the 

U.S. Environmental Protection Agency ("EPA") under the authority of §5(e) ofthe Toxic 

Substance Control Act (TSCA, 15 U.S.C. §2604(e». 

2. Assumption of Liability. The Successor in Interest hereby certifies that, as of the effective date 

of transfer, all actions or omissions governed by the applicable Consent Order limiting 

manufacture, processing, use, distribution in commerce and disposal of the PMN substance, shall 

be the responsibility of the Successor in Interest. Successor in Interest also certifies that it is 

incorporated, licensed, or doing business in the United States in accordance with 40 CPR 

nO.22(a)(3). 

3. Confidential Business Information. The Successor in Interest hereby: 

_ reasserts, 

_ relinquishes, or 

modifies 

all Confidential Business Information ("CBI") claims made by the Company, pursuant to Section 

14 ofTSCA and 40 CPR part 2, for the PMN substance(s). Where "reasserts" or "relinquishes" is 

indicated, that designation shall be deemed to apply to all such claims. Where "modifies" is 

indicated, such modification shall be explained in detail in an attachment to this Notice of 

Transfer. Information which has been previously disclosed to the public (e.g., a chemical identity 

that was not claimed as CBI by the original submitter) would not subsequently be eligible for 

confidential treatment under this Notice of Transfer. 
2 

TOXIC SUBSTANCE CONTROL ACT 

SECTION See) CONSENT ORDER 

NOTICE OF TRANSFER 

(continued) 

Company (Transferor) PMNNumber 

Signature of Authorized Official Date 

Printed Name of Authorized Official 

Title of Authorized Official 

Successor in Interest 

Signature of Authorized Official Date 

Printed Name of Authorized Official 

Title of Authorized Official 

Address 

City, State, Zip Code 
3 

TOXIC SUBSTANCE CONTROL ACT 

SECTION See) CONSENT ORDER 

NOTICE OF TRANSFER 

(continued) 

Successor's Technical Contact 

Address 

City, State, Zip Code 

Phone